Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
MONMOUTH JUNCTION, N.J., Nov. 01, 2017 -- DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Kira Sheinerman, PhD, Chief Executive Officer, will be presenting at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) being held November 1-4, 2017 in Boston, MA.
Session: Clinical trials – Biomarkers including plasma
Title: Sex-specific changes in levels of circulating brain-enriched microRNAs during normal aging and different stages of Alzheimer’s disease
Date/Time: Friday, November 3rd, 2017
Location: Boston Park Plaza, Georgian Room
About DiamiR
DiamiR Biosciences is a privately held molecular diagnostics company focused on developing minimally invasive tests for early detection and monitoring of mild cognitive impairment, Alzheimer's disease, and other conditions. The proprietary technology is based on quantitative analysis of organ-enriched microRNA signatures in plasma and is being developed for screening, patient stratification, as well as disease progression and treatment monitoring. DiamiR collaborates with leading academic centers, disease foundations, and pharma companies. For more information, please visit the company's website at www.diamirbio.com.
Contact:
Kira Sheinerman, PhD, MBA
CEO
917-678-0990
[email protected]
Please Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the results, timing, costs and regulatory review of our studies and clinical trials; the results of studies of our product candidates conducted by others; our ability to obtain future funding on acceptable terms; our ability to obtain regulatory approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights; and innovation by our competitors.
